Chrysostomou S, Eder S, Pototschnig I, Mayer A, Derler M, Mussbacher M
J Cachexia Sarcopenia Muscle. 2024; 15(2):562-574.
PMID: 38302863
PMC: 10995265.
DOI: 10.1002/jcsm.13422.
Kulo A, Smits A, Maleskic S, Van de Velde M, Van Calsteren K, de Hoon J
Bosn J Basic Med Sci. 2016; 17(1):54-60.
PMID: 27968707
PMC: 5341779.
DOI: 10.17305/bjbms.2016.1515.
Mohri K, Okada K, Benet L
Pharm Res. 2005; 22(1):79-85.
PMID: 15771233
DOI: 10.1007/s11095-004-9012-4.
Igarza L, Soraci A, Auza N, Zeballos H
Vet Res Commun. 2002; 26(1):29-37.
PMID: 11860085
DOI: 10.1023/a:1013301620904.
Frihmat R, Cardot J, Beyssac E, Boucher M, Aiache J
Eur J Drug Metab Pharmacokinet. 2001; 25(3-4):205-11.
PMID: 11420891
DOI: 10.1007/BF03192315.
Clinical pharmacokinetics of dexketoprofen.
Barbanoj M, Antonijoan R, Gich I
Clin Pharmacokinet. 2001; 40(4):245-62.
PMID: 11368291
DOI: 10.2165/00003088-200140040-00002.
Chiral bioequivalence: effect of absorption rate on racemic etodolac.
Boni J, Korth-Bradley J, Richards L, CHIANG S, Hicks D, Benet L
Clin Pharmacokinet. 2001; 39(6):459-69.
PMID: 11192477
DOI: 10.2165/00003088-200039060-00006.
Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.
Davies N, Skjodt N
Clin Pharmacokinet. 2000; 38(5):377-92.
PMID: 10843458
DOI: 10.2165/00003088-200038050-00001.
Involvement of the rat gut epithelial and muscular layer, and microflora in chiral inversion and acyl-glucuronidation of R-fenoprofen.
Sattari S, Jamali F
Eur J Drug Metab Pharmacokinet. 1997; 22(2):97-101.
PMID: 9248776
DOI: 10.1007/BF03189791.
Preclinical and clinical development of dexketoprofen.
Mauleon D, Artigas R, Garcia M, Carganico G
Drugs. 1996; 52 Suppl 5:24-45; discussion 45-6.
PMID: 8922555
DOI: 10.2165/00003495-199600525-00005.
Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations.
Li G, Treiber G, Maier K, Walker S, Klotz U
Clin Pharmacokinet. 1993; 25(2):154-63.
PMID: 8403739
DOI: 10.2165/00003088-199325020-00008.
Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs.
Lapicque F, Muller N, Payan E, Dubois N, Netter P
Clin Pharmacokinet. 1993; 25(2):115-23.
PMID: 8403735
DOI: 10.2165/00003088-199325020-00004.
Etodolac clinical pharmacokinetics.
Brocks D, Jamali F
Clin Pharmacokinet. 1994; 26(4):259-74.
PMID: 8013160
DOI: 10.2165/00003088-199426040-00003.
Enantiospecific analysis: applications in bioanalysis and metabolism.
Hutt A, Hadley M, Tan S
Eur J Drug Metab Pharmacokinet. 1994; 19(3):241-51.
PMID: 7867667
DOI: 10.1007/BF03188927.
Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.
Akrawi S, Wedlund P
Eur J Drug Metab Pharmacokinet. 1989; 14(4):269-78.
PMID: 2633921
DOI: 10.1007/BF03190110.
Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis.
Geisslinger G, Schuster O, Stock K, Loew D, BACH G, Brune K
Eur J Clin Pharmacol. 1990; 38(5):493-7.
PMID: 2379535
DOI: 10.1007/BF02336690.
Clinical pharmacokinetics of ketoprofen and its enantiomers.
Jamali F, Brocks D
Clin Pharmacokinet. 1990; 19(3):197-217.
PMID: 2203580
DOI: 10.2165/00003088-199019030-00004.
Stereoselectivity in clinical pharmacokinetics and drug development.
Campbell D
Eur J Drug Metab Pharmacokinet. 1990; 15(2):109-25.
PMID: 2200681
DOI: 10.1007/BF03190194.
Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.
Verbeeck R
Clin Pharmacokinet. 1990; 19(1):44-66.
PMID: 2199127
DOI: 10.2165/00003088-199019010-00004.
Clinical pharmacokinetics 1990.
Matzke G, St Peter W
Clin Pharmacokinet. 1990; 18(1):1-19.
PMID: 2178847
DOI: 10.2165/00003088-199018010-00001.